CLINICAL AND IMMUNOLOGICAL EFFECTS OF IMREG-1 AND IMREG-2, TWO IMMUNOREGULATORS DERIVED FROM LEUKOCYTES NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


CLINICAL AND IMMUNOLOGICAL EFFECTS OF IMREG-1 AND IMREG-2, TWO IMMUNOREGULATORS DERIVED FROM LEUKOCYTES

Int J Immunotherapy; 4(4):199-201 1988. Unique Identifier : AIDSLINE ICDB/90657981
Gottlieb AA; Gottlieb MS; Sinha S; Sizemore R; Kern CH; Imreg Inc., 144 Elk Place, New Orleans, LA 70112

Abstract: The low mol wt subfractions, designated IMREG-1 and IMREG-2, derived from human leukocyte dialysates, have been shown to enhance delayed-type hypersensitivity to recall antigens such as tetanus toxoid. IMREG-1 contains two peptides, Tyr-Gly and Tyr-Gly-Gly, which demonstrate this activity as well as enhancement of cytokine production. These peptides have not previously been shown to affect human immune function and it is of interest to note that they are identical to the amino terminal ends of the enkephalins. The chemical structure of IMREG-2 has not been determined. (4 Refs)
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Adjuvants, Immunologic/ISOLATION & PURIF/*THERAPEUTIC USE Amino Acid Sequence AIDS-Related Complex/IMMUNOLOGY/*THERAPY Clinical Trials CD4-Positive T-Lymphocytes/IMMUNOLOGY Double-Blind Method Human Hypersensitivity, Delayed/IMMUNOLOGY Immunization Leukocytes/*IMMUNOLOGY Lymphokines/IMMUNOLOGY/ISOLATION & PURIF/*THERAPEUTIC USE Neoplasms/IMMUNOLOGY/*THERAPY Random Allocation CLINICAL TRIAL JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/immunology/KWDtherapyadjuvants,immunologic/isolation&purif/KWDtherapeuticuseaminoacidsequenceaids-relatedcomplex/immunology/KWDtherapyclinicaltrialscd4-positivet-lymphocytes/immunologydouble-blindmethodhumanhypersensitivity,delayed/immunologyimmunizationleukocytes/KWDimmunologylymphokines/immunology/isolation&purif/KWDtherapeuticuseneoplasms/immunology/KWDtherapyrandomallocationclinicaltrialjournalarticle
900130
M9010546

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .